MedTrace Logo

Evaluation of Type 2 Diabetes Treatment

NCT03164187 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2024-07-25

No results posted yet for this study

Summary

The aim of this study is to analyze the efficacy of Diabeton 60 MR as intensive sugar-lowering therapy into routine clinical practice, in patients for whom the treating physician has already decided to prescribe this medication. This concerns untreated newly diagnosed patients uncontrolled by diet, and patients uncontrolled by metformin.

Conditions

  • Type2 Diabetes

Interventions

DRUG

Diabeton 60 MR

Administer Diabeton MR 60 mg 1/2 tablet. Increasing dosage of Diabeton MR 60 mg by ½ tablet is recommended if fasting glucose level exceeds 6 mmol/L.

Sponsors & Collaborators

  • Servier Affaires Médicales

    lead INDUSTRY

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-01
Primary Completion
2017-05-15
Completion
2017-06-10

Countries

  • Azerbaijan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03164187 on ClinicalTrials.gov